Developer docs
API playgroundTry for free, no card

Search company profiles

EmCyte Corporation

Full company profile

uuid000bcrl

Namestring
EmCyte Corporation
Legal namestring
EmCyte Corporation
Websiteurl
emcyte.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

EmCyte Corporation is a privately held regenerative medicine company founded in 1999 by Patrick Pennie and headquartered in Fort Myers, Florida. The company designs and manufactures point-of-care autologous biologic preparation systems, with its core platform being the PURE® SupraPhysiologic Concentrating Systems suite. The product portfolio spans centrifuge hardware (Sapphire Centrifuge), disposable concentrating kits (PurePRP SP, PureBMC SP, Progenikine, AspiraDome, ASPIRE, CORE Ultrafiltration System), and an AI-assisted platelet analyzer (RegeniSTAT). Six FDA 510(k) clearances and eight granted U.S. patents anchor the company's regulatory and IP position.

The company sells directly to licensed healthcare professionals — primarily sports medicine physicians, orthopedic specialists, and regenerative medicine practitioners — through a registration-gated e-commerce portal (emcyte.com/emcyte.net) that requires credential verification. The revenue model is a hardware-plus-consumables razor/blade construct: capital equipment drives acquisition, while single-use disposable kits generate recurring revenue. Distribution is domestic only (United States), with no disclosed international sales infrastructure.

Demand generation and customer lock-in are reinforced by an integrated training ecosystem: Gulf Coast Biologics (a nonprofit training center founded 2019), the BioEdge Musculoskeletal Training Program (live-patient training across West and East Coast clinical faculty), and Biofyl Scientific Research (an affiliated regenerative science laboratory). The company also operates a clinical research collaboration program supporting IRB-approved physician-led studies, which doubles as both a customer-acquisition channel and an evidence-generation function.

Short descriptiontext

EmCyte Corporation is a privately held regenerative medicine company founded in 1999 that designs and manufactures FDA-cleared PURE SupraPhysiologic concentrating systems for point-of-care autologous biologic preparation (PRP, BMC, adipose tissue), selling hardware and disposable kits directly to licensed healthcare professionals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFort Myers, United States
HQ citystring
Fort Myers
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine devices, platelet-rich plasma systems, bone marrow concentrate, autologous biologics processing, point-of-care centrifuges
Industry1 code
1Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors)
CodeHLAAAJACPrimaryYes
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Medicine Medical Devices
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Hardware Sales (Centrifuge Systems)
TypeHardware Sales
Description

Sale of Sapphire Centrifuge machines and other processing equipment to healthcare facilities for point-of-care biologic preparation

emcyte.com
2Disposable Concentrating Kits
TypeOne Time License
Description

Single-use kits for PRP, BMC, and adipose tissue processing including PurePRP SP, PureBMC SP, Progenikine, and AspiraDome systems

emcyte.com
3Professional Training Services
TypeProfessional Services
Description

Hands-on in-clinic training programs for physicians and clinicians covering ultrasound-guided injections, biologic formulation, and treatment protocols through BioEdge Musculoskeletal Training

emcyte.com
4Clinical Research Support
TypeProfessional Services
Description

Services including regulatory guidance, IRB-approved clinical trial design, biologic product provisioning, and data collection/analysis support for physician-led research

emcyte.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Standard pricing through registration
ModelOtherBilling cadencePay-as-you-go
Notes

Products sold through registration/account system. 5% discount offered for completing customer satisfaction survey. All sales subject to verification of professional credentials.

emcyte.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1PURE SupraPhysiologic
Description

Proprietary concentrating system technology delivering supraphysiologic concentrations of platelets and biologics for point-of-care applications.

emcyte.com
+9 more records
Core offering1 text field

EmCyte Corporation designs, manufactures and sells the PURE® SupraPhysiologic Concentrating System platform for point-of-care preparation of autologous biologics, including platelet-rich plasma (PRP), bone marrow concentrate (BMC) and adipose tissue concentrate. The product portfolio comprises single-use concentrating kits (PurePRP SP, PureBMC SP, Progenikine), reusable processing instruments (Sapphire Centrifuge, ASPIRE bone marrow harvest kits), the AI-assisted RegeniSTAT platelet analyzer, and the CORE ultrafiltration system, sold directly to licensed healthcare professionals and complemented by paid clinical training programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • ≥80% platelet yield in leukocyte-poor PRP; ≥85% yield in monocyte/neutrophil-rich PRP
+5 more records
Product overview1 text field

EmCyte Corporation offers a comprehensive portfolio of regenerative biologic preparation systems centered on the PURE® SupraPhysiologic Concentrating System platform. The product line includes: AspiraDome (guided buffycoat collection technology), PurePRP SP (platelet-rich plasma concentrating system), PureBMC SP (bone marrow concentrating system), CORE Ultrafiltration System (plasma protein concentration), Progenikine (adipose tissue concentrating system), ASPIRE Bone Marrow Harvesting Systems, RegeniSTAT Platelet Analyzer (AI-assisted analysis), and Sapphire Centrifuge (processing equipment). These products work together to enable point-of-care preparation of autologous biologics including PRP, bone marrow concentrate, and adipose concentrate for regenerative medicine applications.

Product and service10 records
1PURE® SupraPhysiologic Concentrating System
CategoryCore technology platform
Description

Suite of proprietary concentrating technologies empowering physicians to prepare highly potent, customizable autologous biologics at the point of care, with a patient-first, closed-system design supporting PRP, BMC and adipose tissue preparations. Sold to licensed healthcare professionals and medical institutions.

2AspiraDome
CategoryConcentrating kit
Description

Patented guided buffycoat collection device within the PURE SupraPhysiologic system that optimizes platelet and progenitor cell collection, delivering over 80% platelet yield in leukocyte-poor PRP and over 85% yield in monocyte/neutrophil-rich PRP with less than 1% RBC content. Sold to licensed healthcare professionals preparing autologous PRP.

3PurePRP SP (PurePRP® SupraPhysiologic)
CategoryConcentrating kit
Description

Proprietary platelet concentrating system that delivers the highest concentrations of deliverable platelets at the point of care in under 10 minutes using a double-spin technique, allowing physicians to customize PRP formulations (neutrophil-rich/poor) and control final treatment volume. Sold to licensed healthcare professionals performing PRP therapy.

4PureBMC SP (PureBMC® SupraPhysiologic)
CategoryConcentrating kit
Description

Bone marrow concentrating system engineered to deliver superior BMC formulations enriched with hematopoietic stem cells, mesenchymal stem cells, deliverable platelets and cytokine mediators at the point of care, using double-spin technology with preparation time under 10 minutes. Sold to licensed healthcare professionals performing bone marrow concentrate therapy.

5CORE™ Ultrafiltration System
CategoryConcentrating kit
Description

Low-volume 20 kDa plasma ultrafiltration system using polysulfone filtration material that selectively retains key plasma biomolecules (albumin, fibrinogen, growth factors) while removing excess fluid and small waste molecules, enhancing bioactivity in PRP and other autologous biologics. Sold to licensed healthcare professionals.

6Progenikine® Adipose Concentrating System
CategoryConcentrating kit
Description

Adipose concentrating system that compresses adipocytes and eliminates tumescent solution and oil contamination to yield a purified adipose concentrate using dynamic aspiration technology, processing in under five minutes in a fully closed system. Sold to licensed healthcare professionals in plastic and reconstructive surgery and related specialties.

7ASPIRE™ Bone Marrow Harvesting System
CategoryHarvesting device
Description

Advanced clinically sophisticated bone marrow harvesting system featuring side fenestrated architecture with a 180-degree sequestering pattern for minimally invasive, high-purity collection of bone marrow aspirate with preserved cell viability. Sold to licensed healthcare professionals performing bone marrow procedures.

8RegeniSTAT™ Platelet Analyzer
CategoryDiagnostic analyzer
Description

First-of-its-kind platelet analyzer providing full performance analysis comparing baseline platelet values to final PRP biologic, using AI-assisted Viscoelastic Focusing technology to deliver lab-grade analysis from a single drop of blood in under five minutes. Sold to licensed healthcare professionals and clinics requiring point-of-care biologic validation.

9Sapphire Centrifuge
CategoryProcessing instrument
Description

Centrifuge machine designed to streamline regenerative biologics processing, handling EmCyte PRP, BMC and Adipose concentrating systems in a single unit with pre-programmed optimized settings, intuitive touchscreen interface and a 31-pound footprint. Sold to licensed healthcare professionals and clinics as the processing instrument for EmCyte concentrating kits.

10BioEdge Musculoskeletal Training Program
CategoryProfessional training service
Description

Paid in-clinic, live-patient hands-on training program covering ultrasound-guided injections, biologic formulation and treatment protocols, taught by expert clinical board faculty on the West Coast (Dr. Rowan Paul) and East Coast (Dr. Moises Irizarry-Román). Sold to licensed healthcare professionals seeking procedural mastery in regenerative biologic therapies.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Nonprofit educational and training center dedicated to the advancement of regenerative medicine through physician education and hands-on training. Provides clinical publications library and webinar programs supporting EmCyte biologic products. Serves as key GTM channel for training and education.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Independent state-of-the-art regenerative science laboratory dedicated to pioneering breakthroughs in cellular regeneration. Equipped with cutting-edge technology and advanced analytical platforms for fundamental regenerative cell component research and medical applications.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight12 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arthrex is a leading orthopedic medical device company with a prominent autologous PRP concentrating system (Angel System) and an extensive orthopedic sports medicine portfolio. Directly competes with EmCyte for physician-of-the-practice accounts performing PRP/BMC procedures in orthopedics and sports medicine.

TypeDirect peer
Description

Terumo BCT acquired Harvest Technologies and sells SmartPrep and other point-of-care platelet concentration systems to hospitals and cell-therapy labs. Directly overlaps with EmCyte's PurePRP and PureBMC product lines in autologous biologic preparation for regenerative medicine.

TypeDirect peer
Description

Isto Biologics develops autologous bone marrow concentrate and orthobiologic products (e.g., the Magellan system) used in spine and orthopedic surgery. Directly competes with EmCyte's PureBMC and ASPIRE bone marrow harvesting devices in orthobiologics.

TypeDirect peer
Description

Royal Biologics is a pure-play orthobiologics company selling PRP, fibrin, and autologous cell-processing kits to orthopedic and sports medicine physicians. Directly comparable to EmCyte's disposable concentrating kit franchise and competes head-to-head on kit economics.

TypeBroad incumbent
Description

Exactech is a broad orthopedic implant and biologics incumbent with a regenerative-medicine portfolio addressing orthopedic surgeons. Overlaps with EmCyte's sports medicine and orthopedic use cases but operates as a wide-portfolio incumbent rather than a concentrating-systems specialist.

TypeDirect peer
Description

Celling Biosciences (now CorGenix) sells point-of-care autologous cell-processing systems and PRP kits for orthopedic and spine surgeons. Closely comparable to EmCyte's PurePRP/PureBMC franchise in delivery model, customer base, and clinical use cases.

TypeBroad incumbent
Description

Stryker is a diversified medical device incumbent with a sports medicine and biologics business serving orthopedic surgeons. Provides competitive pressure on EmCyte through hospital contracts and bundled orthopedic solutions but does not specialize in point-of-care concentrating systems.

TypeBroad incumbent
Description

DePuy Synthes is Johnson & Johnson's orthopedic and regenerative medicine arm, offering a wide range of sports medicine implants and orthobiologics. Indirectly competes with EmCyte via surgeon relationships and bundled biologic offerings rather than point-of-care concentrating devices.

TypeBroad incumbent
Description

Zimmer Biomet is a global orthopedic incumbent with sports medicine and biologic solutions. Competes for orthopedic surgeon accounts but as a portfolio incumbent rather than a focused autologous concentrating-systems company.

TypeEmerging player
Description

Elutia is an emerging orthobiologics company developing regenerative solutions for soft tissue and bone repair. Partial overlap with EmCyte's regenerative biologics franchise; smaller scale and earlier-stage but addresses adjacent clinical use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EmCyte Corporation

Regenerative Medicine Medical Devicesemcyte.com

EmCyte Corporation is a privately held regenerative medicine company founded in 1999 that designs and manufactures FDA-cleared PURE SupraPhysiologic concentrating systems for point-of-care autologous biologic preparation (PRP, BMC, adipose tissue), selling hardware and disposable kits directly to licensed healthcare professionals.

What EmCyte Corporation does

EmCyte Corporation is a privately held regenerative medicine company founded in 1999 by Patrick Pennie and headquartered in Fort Myers, Florida. The company designs and manufactures point-of-care autologous biologic preparation systems, with its core platform being the PURE® SupraPhysiologic Concentrating Systems suite. The product portfolio spans centrifuge hardware (Sapphire Centrifuge), disposable concentrating kits (PurePRP SP, PureBMC SP, Progenikine, AspiraDome, ASPIRE, CORE Ultrafiltration System), and an AI-assisted platelet analyzer (RegeniSTAT). Six FDA 510(k) clearances and eight granted U.S. patents anchor the company's regulatory and IP position.

The company sells directly to licensed healthcare professionals — primarily sports medicine physicians, orthopedic specialists, and regenerative medicine practitioners — through a registration-gated e-commerce portal (emcyte.com/emcyte.net) that requires credential verification. The revenue model is a hardware-plus-consumables razor/blade construct: capital equipment drives acquisition, while single-use disposable kits generate recurring revenue. Distribution is domestic only (United States), with no disclosed international sales infrastructure.

Demand generation and customer lock-in are reinforced by an integrated training ecosystem: Gulf Coast Biologics (a nonprofit training center founded 2019), the BioEdge Musculoskeletal Training Program (live-patient training across West and East Coast clinical faculty), and Biofyl Scientific Research (an affiliated regenerative science laboratory). The company also operates a clinical research collaboration program supporting IRB-approved physician-led studies, which doubles as both a customer-acquisition channel and an evidence-generation function.

EmCyte Corporation firmographics

Firmographics
Name
EmCyte Corporation
Legal name
EmCyte Corporation
Website
https://emcyte.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
EmCyte Corporation is a privately held regenerative medicine company founded in 1999 that designs and manufactures FDA-cleared PURE SupraPhysiologic concentrating systems for point-of-care autologous biologic preparation (PRP, BMC, adipose tissue), selling hardware and disposable kits directly to licensed healthcare professionals.
Ownership category
akta.pro rank

EmCyte Corporation industry classification

Industry
Product category
Regenerative Medicine Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors) (HLAAAJAC)

Keywords

  • Regenerative medicine devices
  • Platelet-rich plasma systems
  • Bone marrow concentrate
  • Autologous biologics processing
  • Point-of-care centrifuges

Where EmCyte Corporation is headquartered

Location

Headquarters

HQ city
Fort Myers
HQ country
United States
HQ region
North America

Offices3 records

Markets served

EmCyte Corporation business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Hardware Sales (Centrifuge Systems): Sale of Sapphire Centrifuge machines and other processing equipment to healthcare facilities for point-of-care biologic preparation
  2. Disposable Concentrating Kits: Single-use kits for PRP, BMC, and adipose tissue processing including PurePRP SP, PureBMC SP, Progenikine, and AspiraDome systems
  3. Professional Training Services: Hands-on in-clinic training programs for physicians and clinicians covering ultrasound-guided injections, biologic formulation, and treatment protocols through BioEdge Musculoskeletal Training
  4. Clinical Research Support: Services including regulatory guidance, IRB-approved clinical trial design, biologic product provisioning, and data collection/analysis support for physician-led research

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goStandard pricing through registration

Go-to-market motion4 records

Distribution channels3 records

Marketing channels6 records

EmCyte Corporation product offering

Product offering

Core offering

EmCyte Corporation designs, manufactures and sells the PURE® SupraPhysiologic Concentrating System platform for point-of-care preparation of autologous biologics, including platelet-rich plasma (PRP), bone marrow concentrate (BMC) and adipose tissue concentrate. The product portfolio comprises single-use concentrating kits (PurePRP SP, PureBMC SP, Progenikine), reusable processing instruments (Sapphire Centrifuge, ASPIRE bone marrow harvest kits), the AI-assisted RegeniSTAT platelet analyzer, and the CORE ultrafiltration system, sold directly to licensed healthcare professionals and complemented by paid clinical training programs.

Product overview

EmCyte Corporation offers a comprehensive portfolio of regenerative biologic preparation systems centered on the PURE® SupraPhysiologic Concentrating System platform. The product line includes: AspiraDome (guided buffycoat collection technology), PurePRP SP (platelet-rich plasma concentrating system), PureBMC SP (bone marrow concentrating system), CORE Ultrafiltration System (plasma protein concentration), Progenikine (adipose tissue concentrating system), ASPIRE Bone Marrow Harvesting Systems, RegeniSTAT Platelet Analyzer (AI-assisted analysis), and Sapphire Centrifuge (processing equipment). These products work together to enable point-of-care preparation of autologous biologics including PRP, bone marrow concentrate, and adipose concentrate for regenerative medicine applications.

Differentiator

Problem solved

Functional benefit

Brands

  • PURE SupraPhysiologic: Proprietary concentrating system technology delivering supraphysiologic concentrations of platelets and biologics for point-of-care applications.
  • AspiraDome
  • PurePRP SP
  • PureBMC SP
  • CORE
  • Progenikine
  • ASPIRE
  • RegeniSTAT
  • Sapphire Centrifuge
  • BioEdge

Products and services

  • PURE® SupraPhysiologic Concentrating System Suite of proprietary concentrating technologies empowering physicians to prepare highly potent, customizable autologous biologics at the point of care, with a patient-first, closed-system design supporting PRP, BMC and adipose tissue preparations. Sold to licensed healthcare professionals and medical institutions.
  • AspiraDome Patented guided buffycoat collection device within the PURE SupraPhysiologic system that optimizes platelet and progenitor cell collection, delivering over 80% platelet yield in leukocyte-poor PRP and over 85% yield in monocyte/neutrophil-rich PRP with less than 1% RBC content. Sold to licensed healthcare professionals preparing autologous PRP.
  • PurePRP SP (PurePRP® SupraPhysiologic) Proprietary platelet concentrating system that delivers the highest concentrations of deliverable platelets at the point of care in under 10 minutes using a double-spin technique, allowing physicians to customize PRP formulations (neutrophil-rich/poor) and control final treatment volume. Sold to licensed healthcare professionals performing PRP therapy.
  • PureBMC SP (PureBMC® SupraPhysiologic) Bone marrow concentrating system engineered to deliver superior BMC formulations enriched with hematopoietic stem cells, mesenchymal stem cells, deliverable platelets and cytokine mediators at the point of care, using double-spin technology with preparation time under 10 minutes. Sold to licensed healthcare professionals performing bone marrow concentrate therapy.
  • CORE™ Ultrafiltration System Low-volume 20 kDa plasma ultrafiltration system using polysulfone filtration material that selectively retains key plasma biomolecules (albumin, fibrinogen, growth factors) while removing excess fluid and small waste molecules, enhancing bioactivity in PRP and other autologous biologics. Sold to licensed healthcare professionals.
  • Progenikine® Adipose Concentrating System Adipose concentrating system that compresses adipocytes and eliminates tumescent solution and oil contamination to yield a purified adipose concentrate using dynamic aspiration technology, processing in under five minutes in a fully closed system. Sold to licensed healthcare professionals in plastic and reconstructive surgery and related specialties.
  • ASPIRE™ Bone Marrow Harvesting System Advanced clinically sophisticated bone marrow harvesting system featuring side fenestrated architecture with a 180-degree sequestering pattern for minimally invasive, high-purity collection of bone marrow aspirate with preserved cell viability. Sold to licensed healthcare professionals performing bone marrow procedures.
  • RegeniSTAT™ Platelet Analyzer First-of-its-kind platelet analyzer providing full performance analysis comparing baseline platelet values to final PRP biologic, using AI-assisted Viscoelastic Focusing technology to deliver lab-grade analysis from a single drop of blood in under five minutes. Sold to licensed healthcare professionals and clinics requiring point-of-care biologic validation.
  • Sapphire Centrifuge Centrifuge machine designed to streamline regenerative biologics processing, handling EmCyte PRP, BMC and Adipose concentrating systems in a single unit with pre-programmed optimized settings, intuitive touchscreen interface and a 31-pound footprint. Sold to licensed healthcare professionals and clinics as the processing instrument for EmCyte concentrating kits.
  • BioEdge Musculoskeletal Training Program Paid in-clinic, live-patient hands-on training program covering ultrasound-guided injections, biologic formulation and treatment protocols, taught by expert clinical board faculty on the West Coast (Dr. Rowan Paul) and East Coast (Dr. Moises Irizarry-Román). Sold to licensed healthcare professionals seeking procedural mastery in regenerative biologic therapies.

Quantifiable outcome

  • ≥80% platelet yield in leukocyte-poor PRP; ≥85% yield in monocyte/neutrophil-rich PRP
  • +5 more outcomes

Companies that use EmCyte Corporation

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

EmCyte Corporation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

EmCyte Corporation partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Gulf Coast BiologicscoreStrategic or Co-development Partner · 1 January 2019Nonprofit educational and training center dedicated to the advancement of regenerative medicine through physician education and hands-on training. Provides clinical publications library and webinar programs supporting EmCyte biologic products. Serves as key GTM channel for training and education.
  • Biofyl Scientific ResearchcoreStrategic or Co-development PartnerIndependent state-of-the-art regenerative science laboratory dedicated to pioneering breakthroughs in cellular regeneration. Equipped with cutting-edge technology and advanced analytical platforms for fundamental regenerative cell component research and medical applications.

Scale indicators4 records

Recent moves9 records

Expansion highlights12 records

EmCyte Corporation competitors and assessment

Company assessment

Direct peers

  • Arthrex: Arthrex is a leading orthopedic medical device company with a prominent autologous PRP concentrating system (Angel System) and an extensive orthopedic sports medicine portfolio. Directly competes with EmCyte for physician-of-the-practice accounts performing PRP/BMC procedures in orthopedics and sports medicine.
  • Terumo BCT (Harvest Technologies): Terumo BCT acquired Harvest Technologies and sells SmartPrep and other point-of-care platelet concentration systems to hospitals and cell-therapy labs. Directly overlaps with EmCyte's PurePRP and PureBMC product lines in autologous biologic preparation for regenerative medicine.
  • Isto Biologics: Isto Biologics develops autologous bone marrow concentrate and orthobiologic products (e.g., the Magellan system) used in spine and orthopedic surgery. Directly competes with EmCyte's PureBMC and ASPIRE bone marrow harvesting devices in orthobiologics.
  • Royal Biologics: Royal Biologics is a pure-play orthobiologics company selling PRP, fibrin, and autologous cell-processing kits to orthopedic and sports medicine physicians. Directly comparable to EmCyte's disposable concentrating kit franchise and competes head-to-head on kit economics.
  • Celling Biosciences: Celling Biosciences (now CorGenix) sells point-of-care autologous cell-processing systems and PRP kits for orthopedic and spine surgeons. Closely comparable to EmCyte's PurePRP/PureBMC franchise in delivery model, customer base, and clinical use cases.

Broad incumbents

  • Exactech (now part of TPG/Novo Holdings): Exactech is a broad orthopedic implant and biologics incumbent with a regenerative-medicine portfolio addressing orthopedic surgeons. Overlaps with EmCyte's sports medicine and orthopedic use cases but operates as a wide-portfolio incumbent rather than a concentrating-systems specialist.
  • Stryker: Stryker is a diversified medical device incumbent with a sports medicine and biologics business serving orthopedic surgeons. Provides competitive pressure on EmCyte through hospital contracts and bundled orthopedic solutions but does not specialize in point-of-care concentrating systems.
  • DePuy Synthes (Johnson & Johnson): DePuy Synthes is Johnson & Johnson's orthopedic and regenerative medicine arm, offering a wide range of sports medicine implants and orthobiologics. Indirectly competes with EmCyte via surgeon relationships and bundled biologic offerings rather than point-of-care concentrating devices.
  • Zimmer Biomet: Zimmer Biomet is a global orthopedic incumbent with sports medicine and biologic solutions. Competes for orthopedic surgeon accounts but as a portfolio incumbent rather than a focused autologous concentrating-systems company.

Emerging players

  • Elutia (formerly Aziyo Biologics): Elutia is an emerging orthobiologics company developing regenerative solutions for soft tissue and bone repair. Partial overlap with EmCyte's regenerative biologics franchise; smaller scale and earlier-stage but addresses adjacent clinical use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

EmCyte Corporation social profiles

Digital presence

EmCyte Corporation compliance and trust

Trust signal

Compliance2 records

EmCyte Corporation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EmCyte Corporation leadership team

Management profile

Number of profiles

Profiles15 records

EmCyte Corporation subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

EmCyte Corporation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EmCyte Corporation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EmCyte Corporation

What does EmCyte Corporation do?

EmCyte Corporation designs, manufactures and sells the PURE® SupraPhysiologic Concentrating System platform for point-of-care preparation of autologous biologics, including platelet-rich plasma (PRP), bone marrow concentrate (BMC) and adipose tissue concentrate. The product portfolio comprises single-use concentrating kits (PurePRP SP, PureBMC SP, Progenikine), reusable processing instruments (Sapphire Centrifuge, ASPIRE bone marrow harvest kits), the AI-assisted RegeniSTAT platelet analyzer, and the CORE ultrafiltration system, sold directly to licensed healthcare professionals and complemented by paid clinical training programs.

Is EmCyte Corporation a public or private company?

EmCyte Corporation is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was EmCyte Corporation founded?

EmCyte Corporation was founded in 1999. It employs 11 to 50 people.

Where is EmCyte Corporation based?

EmCyte Corporation is headquartered in Fort Myers, United States, in the North America region.

How does EmCyte Corporation make money?

Four revenue lines are on record. Hardware Sales (Centrifuge Systems) is the primary driver. The others are disposable Concentrating Kits, professional Training Services and clinical Research Support.

Who are EmCyte Corporation's main competitors?

Direct peers on record are Arthrex, Terumo BCT (Harvest Technologies), Isto Biologics, Royal Biologics and Celling Biosciences. Broad incumbents are Exactech (now part of TPG/Novo Holdings), Stryker, DePuy Synthes (Johnson & Johnson) and Zimmer Biomet. Elutia (formerly Aziyo Biologics) is listed as an emerging player.

Does EmCyte Corporation have an API?

No public API is recorded for EmCyte Corporation.

What industry is EmCyte Corporation in?

EmCyte Corporation's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAAJAC, Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswirePlatelet Rich Plasma Market to reach USD 2.55 Billion by 2035 at 12.7% CAGRThe global Platelet Rich Plasma market is projected to grow from USD 0.87 billion in 2026 to USD 2.55 billion by 2035, a 12.7% CAGR. Growth is driven by orthopedic clinical evidence, aesthetic demand, and automated preparation standardization. By 2030, AI-guided preparation and proteomics are expected to personalize PRP formulations.openPR.comPlatelet Rich Plasma Market Is Booming Worldwide, Witnessing Strong Growth Through 2033 | Arthrex • Regen Lab • EmCyte CorporationThe article reports on the growth of the Global Platelet Rich Plasma Market from 2026 to 2033, highlighting increased demand and innovation as key drivers. Major companies involved include Arthrex, Regen Lab, and EmCyte Corporation.PRLogSouthwest Florida highlighted as 'global hub for innovation' at 2026 Edison AwardsFive Southwest Florida companies won six awards at the 2026 Edison Awards, including a Gold Edison Award for Fort Myers-based ADDMAN. The event, held April 15-16 in Fort Myers, recognized winners across 50 categories and featured panelists like former Florida Gov. Jeb Bush.GlobeNewswire$1.48 Bn Autologous Conditioned Plasma Markets - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast to 2032A new market research report projects the global autologous conditioned plasma (ACP) market to grow from $729.3 million in 2025 to $1.48 billion by 2032, representing a CAGR of 10.64%. The growth is driven by rising musculoskeletal injuries, increasing preference for non-invasive treatments, and expanding cosmetic and regenerative medicine applications. Notable competitive developments include EmCyte Corporation's acquisition of Cellmedix Holdings LLC and Zimmer Biomet's alliance with OSSIS to expand PRP therapies in orthopedic and sports medicine.PR NewswireGlobal Platelet Rich Plasma (Pure, Leukocyte Rich) Market Research Report 2023: A $1.94 Billion Market by 2030 - Increasing R&D Efforts and Regulatory Approvals for PRP TreatmentsThe global platelet rich plasma market is projected to reach $1.94 billion by 2030, growing at a CAGR of 15.1% from 2023 to 2030, driven by increasing cosmetic surgeries, sporting events, and expanded research in plasma-based therapies. In February 2020, EmCyte Co. acquired Cellmedix Holdings LLC to enhance its product portfolio, while Terumo BCT opened a new manufacturing facility in Costa Rica in September 2021 to grow its U.S. customer base. Key market segments include orthopedics, sports medicine, and cosmetic surgery applications, with North America currently dominating due to wider PRP applications and rising treatment awareness.PR NewswireEmCyte Announces the Acquisition of the Centrepid Platelet ConcentratorEmCyte Corporation announced the acquisition of all assets of Cellmedix Holdings LLC, including the Centrepid Platelet Concentrator system, on February 20, 2020. The acquisition adds three patents and 510(k) clearance to EmCyte's intellectual property portfolio, strengthening its product development capabilities in the regenerative biologics space. CEO Patrick Pennie stated the company remains committed to developing products that make a clinical difference for patients.PR NewswireEmCyte Announces FDA 510(k) Clearance for its Progenikine® Concentrating System for AdiposeEmCyte Corporation announced FDA 510(k) clearance for its Progenikine® Concentrating System for adipose lipoplasty (clearance number K191564), which is cleared for all medical procedures involving the harvesting and transferring of autologous adipose tissue. The system uses centrifugal preparation to extract and concentrate adipose tissue while removing oil contaminants and effluent residuals, allowing regenerative bioactive substances to work without hindering influences. The company sees broad application potential across multiple surgical specialties including plastic, reconstructive, orthopedic, and general surgery.PR NewswireEmCyte Announces FDA 510(k) Clearance for its PureBMC® Supraphysiologic Concentrating SystemEmCyte Corporation announced it received FDA 510(k) clearance for its PureBMC® Supraphysiologic Concentrating System (clearance number K183205), which prepares platelet and cell concentrate from bone marrow aspirate. The system's distinction is that it does not require bone marrow aspirate to be mixed or diluted with whole blood, which the company states preserves cell potency and removes hemolytic oxidative free hemoglobin. CEO Patrick Pennie commented that the system was designed to improve the quality of bone marrow cell concentrate deliverable to clients and has surpassed expectations with consistent performance.PR NewswireEmCyte Corporation® launches a not for profit training organization Gulf Coast Biologics, Inc.EmCyte Corporation announced the launch of Gulf Coast Biologics, Inc., a not-for-profit regenerative medicine training organization based in Fort Myers, Florida. The organization aims to establish evidence-based clinical treatment methodology and provide CME-certified training programs for practitioners in regenerative autologous biologics. Courses will be presented in collaboration with Albert Einstein College of Medicine and Montefiore Medical Center's Center for Continuing Medical Education, with Dr. Peter Everts serving as the keynote speaker.